Your browser doesn't support javascript.
loading
Clinical effects of unintentional pediatric buprenorphine exposures: experience at a single tertiary care center.
Toce, Michael S; Burns, Michele M; O'Donnell, Katherine A.
Affiliation
  • Toce MS; a Harvard Medical Toxicology Program , Boston Children's Hospital , Boston , MA , USA.
  • Burns MM; a Harvard Medical Toxicology Program , Boston Children's Hospital , Boston , MA , USA.
  • O'Donnell KA; b Division of Emergency Medicine, Department of Medicine , Boston Children's Hospital , Boston , MA , USA.
Clin Toxicol (Phila) ; 55(1): 12-17, 2017 Jan.
Article in En | MEDLINE | ID: mdl-27756148
ABSTRACT
CONTEXT Exploratory buprenorphine ingestions in young children have been associated with clinically significant toxicity. However, detailed data on the clinical presentation and management of these patients are lacking. In an attempt to obtain more comprehensive data, we sought to examine a single center cohort of patients with report of buprenorphine exposure and provide descriptive analysis of rates of respiratory depression, time to respiratory depression, interventions, disposition, and outcomes. STUDY

DESIGN:

We performed a retrospective cohort study at a single pediatric tertiary care center of children between the age of 6 months and 7 years of age hospitalized between 1 January 2006 and 1 September 2014 with report of buprenorphine or buprenorphine/naloxone exposure. Patients with possible exposure to more than one agent were excluded. We extracted clinical findings, including time to respiratory depression, interventions, and disposition from the medical record.

RESULTS:

Eighty-eight patients met the inclusion criteria. Seven patients were excluded. The median age was 24 months [IQR 18-30]. 20 patients (23%) received activated charcoal while 48 (55%) were treated with naloxone. 36 (41%) patients were admitted to the ICU. Observed clinical effects included respiratory depression (83%), oxygen saturation by pulse oximetry (SpO2) < 93% (28%), depressed mental status (80%), miosis (77%), and emesis (45%). Median time from exposure to respiratory depression was 263 min [IQR 105-486]. The median hospital length of stay was 22 h [IQR 20-26] and was positively associated with estimated exposure dose (p = 0.002).

CONCLUSION:

Pediatric patients exposed to buprenorphine are likely to exhibit signs and symptoms of opioid toxicity, including respiratory depression, altered mental status and miosis. Although the majority of patients developed signs of clinical toxicity within 8 h of reported exposure, the optimum duration of monitoring remains unclear.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Buprenorphine / Buprenorphine, Naloxone Drug Combination / Analgesics, Opioid / Narcotic Antagonists Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Child / Child, preschool / Female / Humans / Infant / Male Language: En Journal: Clin Toxicol (Phila) Journal subject: TOXICOLOGIA Year: 2017 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Buprenorphine / Buprenorphine, Naloxone Drug Combination / Analgesics, Opioid / Narcotic Antagonists Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Child / Child, preschool / Female / Humans / Infant / Male Language: En Journal: Clin Toxicol (Phila) Journal subject: TOXICOLOGIA Year: 2017 Document type: Article Affiliation country: United States